Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Publication number: 20240084008
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 14, 2024
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
  • Publication number: 20240084007
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 14, 2024
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
  • Publication number: 20240082177
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 14, 2024
    Applicants: MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Benjamin Rubin, Mark Gilbert, Jinkyu Jung
  • Patent number: 11926656
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 12, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Patent number: 11925664
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 12, 2024
    Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Branden Moriarity, Beau Webber, David Largaespada, Modassir Choudhry, Steven A. Rosenberg
  • Patent number: 11925558
    Abstract: Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: March 12, 2024
    Assignee: The United States of America, As Represented By The Secretary, Department of Health and Human Services
    Inventors: June-Hong Kim, Robert J. Lederman, Ozgur Kocaturk
  • Patent number: 11921181
    Abstract: Provided herein are methods and systems for high-resolution, cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 5, 2024
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Daniel Salo Reich, Erin Savner Beck, Govind Nair, Neville Dali Gai
  • Patent number: 11918638
    Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Thomas Charles McCarty
  • Patent number: 11918640
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: March 5, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11918639
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: March 5, 2024
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Service
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
  • Patent number: 11905313
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.
    Inventor: Surender Khurana
  • Patent number: 11906528
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: February 20, 2024
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 11905564
    Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhi-Ming Zheng, Junfen Xu, Jun Zhu, Yanqin Yang, Xiaohong Wang
  • Patent number: 11904057
    Abstract: This disclosure provides novel peptide hydrogels containing encapsulated nanoparticles comprising nucleic acid molecules (such as miRNA) that can undergo multiple gel-to-solution (gel-sol) and solution-to-gel (sol-gel) phase transitions, and their use, such as for controlled delivery of nucleic acid molecules to a subject.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Schneider, Poulami Majumder, Chuong Hoang, Anand Singh
  • Patent number: 11906530
    Abstract: Methods are disclosed herein for determining whether a subject has a Tauopathy, such as Pick disease, Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or argyrophilic grain disease (AGD). These methods utilize an amyloid seeding assay.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Eri Saijo, Allison Lindsey Kraus, Michael Anthony Metrick, II
  • Patent number: 11897933
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Patent number: 11897845
    Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 13, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Patent number: 11898166
    Abstract: Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Raul E. Vizcardo, Nicholas P. Restifo
  • Patent number: 11897875
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: February 13, 2024
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Patent number: 11898207
    Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg